Core Insights - Zefiro Methane Corp. announced that its CEO and three Board members purchased a total of 723,000 common shares in the open market, reflecting confidence in the company's strategic direction and long-term value creation potential [1][2]. Company Developments - The CEO, Catherine Flax, stated that Zefiro has been focusing on strengthening its financial and operational foundation, enhancing revenue-generating activities, and building partnerships across various channels [3]. - The company is actively engaged in initiatives related to orphan well retirement, methane emissions reduction, environmental credit generation, and developing scalable solutions for verified emissions abatement [3]. Insider Transactions - The recent insider purchases were made independently and will be reported in regulatory filings as required [4].

Core Insights - Cardiol Therapeutics Inc. announced significant findings from the Phase II ARCHER trial, demonstrating that CardiolRx™ improves heart structure in patients with acute myocarditis, supporting its potential for broader applications in inflammatory cardiac conditions [2][4][5] Group 1: Trial Results - The ARCHER trial showed a significant reduction in left ventricular (LV) mass by 9.2 grams (from 130.3g in placebo to 121.1g in the active group, p=0.0117), indicating meaningful structural recovery [3][8] - Extracellular volume (ECV) decreased by 3.7 mL (from 37.3mL in placebo to 33.6mL in the active group, p=0.0538), and intracellular volume (ICV) reduced by 5.6 mL (from 91.2mL in placebo to 85.6mL in the active group, p=0.0928) [8][9] - Left atrial end systolic volume (LAESV) was reduced by 8.1 mL (p=0.0376) and left ventricular end diastolic volume (LVEDV) decreased by 7.4 mL (p=0.0981), reflecting improved heart function [8][9] Group 2: Clinical Implications - The results provide clinical evidence that CardiolRx™ can reduce inflammation-driven structural damage in the heart, a key factor in heart failure progression [4][5] - The findings support the scientific rationale for Cardiol's lead Phase III program in recurrent pericarditis and indicate potential for development across various inflammatory cardiac conditions [4][5][17] Group 3: Company Overview - Cardiol Therapeutics is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with CardiolRx™ as its lead candidate [15][18] - The company is also advancing CRD-38, a next-generation small molecule targeting chronic inflammatory heart conditions [18]

Core Viewpoint - INEO Tech Corp. announces a non-brokered private placement to raise up to $2,345,000 by issuing up to 156,355,684 common shares at a price of $0.015 per share [1][3]. Offering Details - The Offering allows eligible INEO shareholders to participate, subject to compliance with applicable securities laws [2][8]. - The rights offering previously announced on November 24, 2025, has been terminated due to objections, but existing shareholders still have the opportunity to participate in this Offering [3]. Use of Proceeds - Net proceeds from the Offering are intended for working capital and general corporate purposes, including inventory purchases, deployments, product/engineering, and sales & marketing initiatives [4]. - The allocation of proceeds is as follows: - Inventory Purchase and Customer Deployments: $1,600,000 (assuming 100% of the offering) - General and Administrative Expenses: $745,000 (assuming 100% of the offering) [5]. Closing and Conditions - The Offering is subject to customary conditions, including acceptance by the TSX Venture Exchange, and may close in one or more tranches [6]. - All securities issued will be subject to a statutory hold period of four months plus one day from the closing date [6]. Insider Participation - Coenda Investments Holding Corp. has the right to maintain its interest in the Company by participating in the Offering, with a notification deadline of December 5, 2025 [9]. - Other insiders may also participate, and such participation is expected to be exempt from formal valuation and minority shareholder approval requirements [9]. Company Overview - INEO Tech Corp. operates at the intersection of in-store retail media and loss prevention, with a focus on digital signage and retail analytics through its subsidiary INEO Solutions Inc. [10]. - The company’s patented technology integrates Electronic Article Surveillance (EAS) with digital displays to help retailers reduce theft while generating media revenue [10].

Core Viewpoint - GR Silver Mining Ltd. has announced a bought deal financing agreement to raise $13,000,200 through the sale of 43,334,000 units at a price of $0.30 per unit, aimed at advancing its Plomosas Project in Mexico and for general corporate purposes [1][3]. Group 1: Offering Details - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at an exercise price of $0.42 for 36 months [2]. - The offering includes a provision for the underwriters to increase the offering size by up to an additional 3,999,333 units and a 15% increase in the private placement offering [4]. - The closing of the offerings is expected around the week of December 15, 2025, subject to regulatory approvals [8]. Group 2: Use of Proceeds - The net proceeds from the offerings will be allocated to advancing the Plomosas Project, working capital, and general corporate purposes [3]. Group 3: Regulatory and Compliance Information - The LIFE Offering will be conducted under the 'listed issuer financing exemption' and will be free-trading under applicable Canadian securities laws, except in Quebec [5]. - The private placement offering will be available to accredited investors and will have a statutory hold period of four months and one day from closing [7]. Group 4: Underwriters and Fees - The underwriters will receive a cash commission of 6.0% of the aggregate gross proceeds and broker warrants equal to 6.0% of the units sold, with each broker warrant allowing the purchase of one unit at the offering price for 36 months [9].

Core Points - Pacific Ridge Exploration Ltd. has granted 1,850,000 incentive stock options to various stakeholders at an exercise price of CAD$0.25 for a period of five years [1] - The company aims to become British Columbia's leading copper exploration company, with its flagship project being the Kliyul copper-gold project [2] - The Kliyul Main Zone hosts an Inferred Mineral Resource of 334.1 million tonnes grading 0.33% CuEq, which includes 0.15% copper, 0.26 g/t gold, and 0.95 g/t silver [2] - The company also has a diverse project portfolio that includes the RDP, Chuchi, Onjo, and Redton copper-gold projects, all located in British Columbia [2] - The estimated recoveries for the Kliyul project are 80% for copper, 60% for gold, and 60% for silver [3] Company Overview - Pacific Ridge is a subsidiary of Fiore Group and focuses on copper exploration in British Columbia [2] - The company acknowledges that its projects are located in the traditional territories of several Indigenous nations [2] - The Kliyul project is strategically located near existing infrastructure, enhancing its potential for development [2]

Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - Gold X2 Mining Inc. (TSXV: AUXX) (OTCQB: GSHRF) (FSE: DF8) ("Gold X2" or the "Company"), is pleased to announce that it has completed the previously announced plan of arrangement (the "Arrangement") to acquire all the issued and outstanding common shares of Kesselrun Resources Ltd. ("Kesselrun").The Arrangement results in Gold X2 acquiring Kesselrun's 100% owned Huronian Gold Project (the "Huronian Gold Project"), which sits on the western ...

Core Insights - Olive Resource Capital Inc. reported a record third-quarter investment performance of 61.8% and a net income of $5.2 million for the three months ended September 30, 2025 [1][4] - The company's investment portfolio is valued at $14.35 million as of September 30, 2025, reflecting significant growth from previous periods [4][5] - The net asset value (NAV) per share increased to $0.128, marking a year-to-date increase of 113.5% [4][13] Financial Performance - For Q3 2025, Olive reported a net income of $5,170,183, equating to $0.05 per share, compared to a net loss of $147,715 for the same period in 2024 [4][9] - The total income for the nine months ended September 30, 2025, was $7,205,626, with a basic and diluted income per share of $0.07 [4][10] - The increase in income of $7,353,341 is attributed to higher unrealized and realized gains on investments compared to the same period last year [10] Investment Portfolio - The portfolio includes significant investments in various sectors, with notable increases in the value of Omai Gold Mines Corp. and Sterling Metals Corp. [3][4] - The total value of the investment portfolio has grown from $6.42 million at the end of 2024 to $14.35 million by September 30, 2025 [5][7] - The company holds 1,000,000 common shares in treasury pending cancellation, with a total of 106,144,709 common shares outstanding [8] Market Positioning - The company’s president highlighted that Olive's portfolio is well-positioned to benefit from ongoing market trends, including resource underinvestment and monetary debasement [3] - The strong performance is expected to continue as the company capitalizes on the inability of existing assets to meet demand growth forecasts [3]

Core Insights - Kiora Pharmaceuticals has been granted a new U.S. patent (US-12,472,263) for additional formulations of the KIO-100 family of anti-inflammatory compounds, enhancing the therapeutic potential of KIO-104 [1][2] Company Overview - Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing advanced therapies for retinal diseases, utilizing innovative small molecules to address vision loss [4] - The company is developing KIO-301 for retinitis pigmentosa, choroideremia, and Stargardt disease, and KIO-104 for retinal inflammation [4] Product Development - KIO-104 is a non-steroidal anti-inflammatory small molecule that inhibits dihydroorotate dehydrogenase (DHODH) and is currently undergoing a Phase 2 clinical trial (KLARITY) for treating retinal inflammation [2][3] - The KLARITY study aims to enroll up to 28 patients with macular edema, a condition linked to inflammation and adverse vision changes [3] Clinical Trials - KIO-104 has shown clinical proof-of-concept in a Phase 1 trial for non-infectious uveitis and is now being evaluated at higher doses for various retinal inflammatory conditions [3]

Core Insights - Astra Exploration Inc. is providing a progress update on its exploration activities at the La Manchuria Gold and Silver Project in Santa Cruz, Argentina, highlighting significant advancements in its Phase II drill program [1][7]. Phase II Drill Program - The company is approximately halfway through its 10,000 metre Phase II drill program, having completed 5,119 metres of diamond drilling in 25 holes, with initial assay results expected in December and the majority in early 2026 [2][3]. - Drilling has paused for results and is set to resume in early 2026 [2]. Exploration Highlights - The Phase II drill program aims to test lateral extensions of the shallow epithermal vein system and a new 3-D geophysical targeting model, with all drill holes intersecting veins and/or veinlets showing evidence of mineralization [3][4]. - The strike length of the Main Zone has been extended from approximately 500 to 800 metres, particularly in the West Feeder veins, and a continuous vein of at least 200 metres of strike length has been confirmed in the Eastern Zone [4][8]. - A new parallel structure has been intersected about 350 metres northeast of the Eastern Zone, demonstrating the effectiveness of the 3-D geophysical model in targeting mineralized veins [4][8]. Geological and Geophysical Work - Prior to drilling, the company conducted detailed geological mapping and reprocessing of geophysical data, expanding regional ground magnetics by an additional 150 line-kilometres [5]. - The resistivity reprocessing has identified fault blocks and optimal elevations for targeting prospective veins in the West Feeder area, which hosts some of the thickest and highest-grade veins known in the system [6]. Future Plans - The company plans to continue testing the 3-D geophysical model with more drilling within the existing survey boundary and expand the survey to other areas of the project before resuming drilling [4].

Core Viewpoint - NexGen Energy Ltd. has announced its highest-grade uranium assay results to date from its 100%-owned Patterson Corridor East (PCE) project, indicating significant mineralization potential in the region [1][2][3] Group 1: Assay Results - Drill hole RK-25-256 returned 5.5 meters at 21.4% U3O8, including 2.5 meters at 46.1% U3O8 and 0.5 meters at 74.8% U3O8, marking a notable high-grade intersection [1][6] - The high-grade intersection in RK-25-256 is located 119 meters down-dip from drill hole RK-25-232 and 51 meters down-dip from RK-25-254, suggesting a continuous high-grade mineralization trend [2] Group 2: Mineralization Insights - The frequency of ultra-high-grade intercepts at both Arrow and PCE indicates a significant mineralizing event in the southwest Athabasca Basin [4] - The PCE project is interpreted to have a minimum dip extent of 215 meters of intense high-grade uranium mineralization from RK-25-254 to RK-24-222 [2] Group 3: Company Strategy and Positioning - NexGen is developing a uranium project portfolio aimed at providing a multi-generational nuclear fuel supply, emphasizing economic, environmental, and social outcomes [5] - The company controls over 190,000 hectares across 140 kilometers in the southwest Athabasca Basin, positioning itself as a leader in uranium exploration and development [5]